Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Identifieur interne : 004539 ( Ncbi/Curation ); précédent : 004538; suivant : 004540Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
Auteurs : Nobubelo K. Ngandu [Afrique du Sud] ; Jonathan M. Carlson ; Denis R. Chopera ; Nonkululeko Ndabambi ; Quarraisha Abdool Karim ; Salim Abdool Karim ; Carolyn WilliamsonSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Agents antiVIH (administration et posologie), Agents antiVIH (pharmacologie), Agents antiVIH (usage thérapeutique), Analyse de séquence d'ADN, Anti-infectieux (administration et posologie), Anti-infectieux (pharmacologie), Anti-infectieux (usage thérapeutique), Charge virale, Crèmes, mousses et gels vaginaux (usage thérapeutique), Essais cliniques comme sujet, Femelle, Humains, Infections à VIH (), Infections à VIH (transmission), Infections à VIH (virologie), Phylogénie, Produits du gène gag du virus de l'immunodéficience humaine (génétique), Prophylaxie pré-exposition, République d'Afrique du Sud (épidémiologie), Résultat thérapeutique, Ténofovir (usage thérapeutique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- administration et posologie : Agents antiVIH, Anti-infectieux.
- génétique : Produits du gène gag du virus de l'immunodéficience humaine, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Agents antiVIH, Anti-infectieux.
- usage thérapeutique : Agents antiVIH, Anti-infectieux, Crèmes, mousses et gels vaginaux, Infections à VIH, Ténofovir.
- virologie : Infections à VIH.
- épidémiologie : République d'Afrique du Sud.
- Analyse de séquence d'ADN, Charge virale, Essais cliniques comme sujet, Femelle, Humains, Infections à VIH, Phylogénie, Prophylaxie pré-exposition, Résultat thérapeutique, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Anti-HIV Agents (administration & dosage), Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), Anti-Infective Agents (administration & dosage), Anti-Infective Agents (pharmacology), Anti-Infective Agents (therapeutic use), Clinical Trials as Topic, Female, HIV Infections (prevention & control), HIV Infections (transmission), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), Humans, Phylogeny, Pre-Exposure Prophylaxis, Sequence Analysis, DNA, South Africa (epidemiology), Tenofovir (therapeutic use), Treatment Outcome, Vaginal Creams, Foams, and Jellies (therapeutic use), Viral Load, gag Gene Products, Human Immunodeficiency Virus (genetics).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Anti-Infective Agents.
- chemical , genetics : gag Gene Products, Human Immunodeficiency Virus.
- chemical , pharmacology : Anti-HIV Agents, Anti-Infective Agents.
- chemical , therapeutic use : Anti-HIV Agents, Anti-Infective Agents, Tenofovir, Vaginal Creams, Foams, and Jellies.
- drug effects : HIV-1.
- epidemiology : South Africa.
- genetics : HIV-1.
- prevention & control : HIV Infections.
- transmission : HIV Infections.
- virology : HIV Infections.
- Clinical Trials as Topic, Female, Humans, Phylogeny, Pre-Exposure Prophylaxis, Sequence Analysis, DNA, Treatment Outcome, Viral Load.
Abstract
Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics.
DOI: 10.1097/QAI.0000000000001458
PubMed: 28797020
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000984
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000984
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000984
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004539
Links to Exploration step
pubmed:28797020Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.</title><author><name sortKey="Ngandu, Nobubelo K" sort="Ngandu, Nobubelo K" uniqKey="Ngandu N" first="Nobubelo K" last="Ngandu">Nobubelo K. Ngandu</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Carlson, Jonathan M" sort="Carlson, Jonathan M" uniqKey="Carlson J" first="Jonathan M" last="Carlson">Jonathan M. Carlson</name></author><author><name sortKey="Chopera, Denis R" sort="Chopera, Denis R" uniqKey="Chopera D" first="Denis R" last="Chopera">Denis R. Chopera</name></author><author><name sortKey="Ndabambi, Nonkululeko" sort="Ndabambi, Nonkululeko" uniqKey="Ndabambi N" first="Nonkululeko" last="Ndabambi">Nonkululeko Ndabambi</name></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name></author><author><name sortKey="Abdool Karim, Salim" sort="Abdool Karim, Salim" uniqKey="Abdool Karim S" first="Salim" last="Abdool Karim">Salim Abdool Karim</name></author><author><name sortKey="Williamson, Carolyn" sort="Williamson, Carolyn" uniqKey="Williamson C" first="Carolyn" last="Williamson">Carolyn Williamson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28797020</idno><idno type="pmid">28797020</idno><idno type="doi">10.1097/QAI.0000000000001458</idno><idno type="wicri:Area/PubMed/Corpus">000984</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000984</idno><idno type="wicri:Area/PubMed/Curation">000984</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000984</idno><idno type="wicri:Area/PubMed/Checkpoint">000984</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000984</idno><idno type="wicri:Area/Ncbi/Merge">004539</idno><idno type="wicri:Area/Ncbi/Curation">004539</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.</title><author><name sortKey="Ngandu, Nobubelo K" sort="Ngandu, Nobubelo K" uniqKey="Ngandu N" first="Nobubelo K" last="Ngandu">Nobubelo K. Ngandu</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa;†Currently, Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa;‡Microsoft Research, Redmond, WA; and§Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Carlson, Jonathan M" sort="Carlson, Jonathan M" uniqKey="Carlson J" first="Jonathan M" last="Carlson">Jonathan M. Carlson</name></author><author><name sortKey="Chopera, Denis R" sort="Chopera, Denis R" uniqKey="Chopera D" first="Denis R" last="Chopera">Denis R. Chopera</name></author><author><name sortKey="Ndabambi, Nonkululeko" sort="Ndabambi, Nonkululeko" uniqKey="Ndabambi N" first="Nonkululeko" last="Ndabambi">Nonkululeko Ndabambi</name></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name></author><author><name sortKey="Abdool Karim, Salim" sort="Abdool Karim, Salim" uniqKey="Abdool Karim S" first="Salim" last="Abdool Karim">Salim Abdool Karim</name></author><author><name sortKey="Williamson, Carolyn" sort="Williamson, Carolyn" uniqKey="Williamson C" first="Carolyn" last="Williamson">Carolyn Williamson</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (pharmacology)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Anti-Infective Agents (administration & dosage)</term><term>Anti-Infective Agents (pharmacology)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Female</term><term>HIV Infections (prevention & control)</term><term>HIV Infections (transmission)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Phylogeny</term><term>Pre-Exposure Prophylaxis</term><term>Sequence Analysis, DNA</term><term>South Africa (epidemiology)</term><term>Tenofovir (therapeutic use)</term><term>Treatment Outcome</term><term>Vaginal Creams, Foams, and Jellies (therapeutic use)</term><term>Viral Load</term><term>gag Gene Products, Human Immunodeficiency Virus (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (pharmacologie)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Analyse de séquence d'ADN</term><term>Anti-infectieux (administration et posologie)</term><term>Anti-infectieux (pharmacologie)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Charge virale</term><term>Crèmes, mousses et gels vaginaux (usage thérapeutique)</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (transmission)</term><term>Infections à VIH (virologie)</term><term>Phylogénie</term><term>Produits du gène gag du virus de l'immunodéficience humaine (génétique)</term><term>Prophylaxie pré-exposition</term><term>République d'Afrique du Sud (épidémiologie)</term><term>Résultat thérapeutique</term><term>Ténofovir (usage thérapeutique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>gag Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Anti-Infective Agents</term><term>Tenofovir</term><term>Vaginal Creams, Foams, and Jellies</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Produits du gène gag du virus de l'immunodéficience humaine</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Anti-infectieux</term><term>Crèmes, mousses et gels vaginaux</term><term>Infections à VIH</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>République d'Afrique du Sud</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Female</term><term>Humans</term><term>Phylogeny</term><term>Pre-Exposure Prophylaxis</term><term>Sequence Analysis, DNA</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de séquence d'ADN</term><term>Charge virale</term><term>Essais cliniques comme sujet</term><term>Femelle</term><term>Humains</term><term>Infections à VIH</term><term>Phylogénie</term><term>Prophylaxie pré-exposition</term><term>Résultat thérapeutique</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:28797020
|texte= Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:28797020" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |